Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBT: 2019-2025

Historic EBT for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.

  • Allogene Therapeutics' EBT rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.1 million for FY2024, which is 21.43% up from last year.
  • Latest data reveals that Allogene Therapeutics reported EBT of -$41.3 million as of Q3 2025, which was up 18.82% from -$50.9 million recorded in Q2 2025.
  • Allogene Therapeutics' EBT's 5-year high stood at $1.9 million during Q4 2021, with a 5-year trough of -$97.0 million in Q1 2023.
  • For the 3-year period, Allogene Therapeutics' EBT averaged around -$65.0 million, with its median value being -$64.1 million (2024).
  • In the last 5 years, Allogene Therapeutics' EBT skyrocketed by 102.76% in 2021 and then tumbled by 5,046.54% in 2022.
  • Allogene Therapeutics' EBT (Quarterly) stood at $1.9 million in 2021, then crashed by 5,046.54% to -$93.6 million in 2022, then increased by 15.80% to -$78.8 million in 2023, then increased by 27.02% to -$57.5 million in 2024, then surged by 36.60% to -$41.3 million in 2025.
  • Its EBT stands at -$41.3 million for Q3 2025, versus -$50.9 million for Q2 2025 and -$59.8 million for Q1 2025.